TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Mental Stress Reduction in Defibrillator Patients
Brief Summary: The purpose of this study is to assess the effectiveness of a 10 week program of Stress Management versus control Patient Education sessions on cardiac responses to mental stress in veterans with Implantable Cardioverter-Defibrillators


Options:
A: Arm Label: Aerobic Exercise Program; Type: EXPERIMENTAL; Interventions: Behavioral: Aerobic Exercise Program | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Aerobic Exercise Program; Assigned to Arm(s): Aerobic Exercise Program
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: rehabilitation | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: rehabilitation; Assigned to Arm(s): 1
C: Arm Label: Cognitive Behavior Therapy - males; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behaviour Therapy (CBT) | Arm Label: Cognitive Behavior Therapy - females; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behaviour Therapy (CBT) | Arm Label: Usual Cardiac Care - Males; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Cardiac Care (UCC) | Arm Label: Usual Cardiac Care - females; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Cardiac Care (UCC) | Intervention Type: BEHAVIORAL; Name: Cognitive Behaviour Therapy (CBT); Assigned to Arm(s): Cognitive Behavior Therapy - females, Cognitive Behavior Therapy - males | Intervention Type: OTHER; Name: Usual Cardiac Care (UCC); Assigned to Arm(s): Usual Cardiac Care - Males, Usual Cardiac Care - females
D: Arm Label: Cognitive Behavioral Stress Management; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Behavioral Stress Management (CBSM) | Arm Label: Patient Education; Type: ACTIVE_COMPARATOR; Interventions: Other: Patient Education | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Stress Management (CBSM); Assigned to Arm(s): Cognitive Behavioral Stress Management | Intervention Type: OTHER; Name: Patient Education; Assigned to Arm(s): Patient Education

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Does Massage With or Without Aromatherapy Reduce Infant's Distress After Craniofacial Surgery? A Randomized Controlled Trial
Brief Summary: This study aims to determine the effect of massage with or without aromatherapy on infant´s level of distress


Options:
A: Arm Label: Pentacel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pentacel (DPTaP+Hib) | Arm Label: Prevnar; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prevnar (conjugated pneumococcal vaccine) | Intervention Type: DRUG; Name: Pentacel (DPTaP+Hib); Assigned to Arm(s): Pentacel | Intervention Type: DRUG; Name: Prevnar (conjugated pneumococcal vaccine); Assigned to Arm(s): Prevnar
B: Arm Label: OH; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Hernia repair | Arm Label: LH; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Hernia repair | Intervention Type: PROCEDURE; Name: Hernia repair; Assigned to Arm(s): LH, OH
C: Arm Label: A; Type: OTHER; Interventions: Other: aromatherapy massage | Arm Label: B; Type: OTHER; Interventions: Other: aromatherapy massage | Arm Label: C; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: aromatherapy massage; Assigned to Arm(s): A, B
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: pillow | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: pillow; Assigned to Arm(s): 1

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Does Massage With or Without Aromatherapy Reduce Infant's Distress After Craniofacial Surgery? A Randomized Controlled Trial
Brief Summary: This study aims to determine the effect of massage with or without aromatherapy on infant´s level of distress


Options:
A: Arm Label: Self-monitoring of BF and intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Self-monitoring of BF and intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Self-monitoring of BF and intervention; Assigned to Arm(s): Self-monitoring of BF and intervention
B: Arm Label: Co-bedding; Type: EXPERIMENTAL; Interventions: Procedure: Co-bedding (caring for twins in the same incubator) | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Co-bedding (caring for twins in the same incubator); Assigned to Arm(s): Co-bedding
C: Arm Label: A; Type: OTHER; Interventions: Other: aromatherapy massage | Arm Label: B; Type: OTHER; Interventions: Other: aromatherapy massage | Arm Label: C; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: aromatherapy massage; Assigned to Arm(s): A, B
D: Arm Label: Massage; Type: EXPERIMENTAL; Interventions: Behavioral: massage | Arm Label: Quiet Time; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: quiet time | Intervention Type: BEHAVIORAL; Name: massage; Assigned to Arm(s): Massage | Intervention Type: BEHAVIORAL; Name: quiet time; Assigned to Arm(s): Quiet Time

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Double-blinded Interventional Study on the Effects of MFGM-enriched Formula With Reduced Energy and Protein Content on Growth and Development
Brief Summary: Formula-fed infants differ from breast-fed infants in the growth pattern, risk for obesity and cardiovascular diseases, neurological development and morbidity in infections.

The investigators' hypothesis is that a modified formula with reduced energy and protein content and enrichment with Milk Fat Globule Membrane (MFGM) containing bioactive proteins and phospholipids will reduce the difference between formula-fed and breast-fed infants.


Options:
A: Arm Label: Probiotic; Type: ACTIVE_COMPARATOR; Interventions: Other: Yogurt drink with probiotic bacteria BB12 | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: OTHER; Name: Yogurt drink with probiotic bacteria BB12; Assigned to Arm(s): Probiotic | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Control
B: Arm Label: Bifidobacterium animalis subsp. lactis; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Bifidobacterium animalis subsp. lactis | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Bifidobacterium animalis subsp. lactis; Assigned to Arm(s): Bifidobacterium animalis subsp. lactis
C: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: follow on formula without probiotics | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: follow on formula with Lactobacillus salivarius CECT5713 | Intervention Type: DIETARY_SUPPLEMENT; Name: follow on formula without probiotics; Assigned to Arm(s): A | Intervention Type: DIETARY_SUPPLEMENT; Name: follow on formula with Lactobacillus salivarius CECT5713; Assigned to Arm(s): B
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Modified formula (MFGM-enriched formula with reduced energy and protein content) | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 3; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Modified formula (MFGM-enriched formula with reduced energy and protein content); Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III of Recombinant Human Activated Protein C and Low Dose of Hydrocortisone and Fludrocortisone in Adult Septic Shock
Brief Summary: This study aims at comparing the efficacy and safety of recombinant human activated protein C to that of low dose of corticosteroids and at investigating the interaction between these drugs in the management of septic shock


Options:
A: Arm Label: Fenoldopam; Type: EXPERIMENTAL; Interventions: Drug: fenoldopam | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: fenoldopam; Assigned to Arm(s): Fenoldopam | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: IV acetaminophen & IV propofol; Type: EXPERIMENTAL; Interventions: Drug: IV acetaminophen & IV propofol | Arm Label: IV acetaminophen & IV dexmedetomidine; Type: EXPERIMENTAL; Interventions: Drug: IV acetaminophen & IV dexmedetomidine | Arm Label: IV propofol & placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV propofol & placebo | Arm Label: IV dexmedetomidine & placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV dexmedetomidine & placebo | Intervention Type: DRUG; Name: IV acetaminophen & IV propofol; Assigned to Arm(s): IV acetaminophen & IV propofol | Intervention Type: DRUG; Name: IV acetaminophen & IV dexmedetomidine; Assigned to Arm(s): IV acetaminophen & IV dexmedetomidine | Intervention Type: DRUG; Name: IV propofol & placebo; Assigned to Arm(s): IV propofol & placebo | Intervention Type: DRUG; Name: IV dexmedetomidine & placebo; Assigned to Arm(s): IV dexmedetomidine & placebo
C: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebos | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: hydrocortisone and fludrocortisone and placebo | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human activated protein C and placebos | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human activated protein C and hydrocortisone and fludrocortisone | Intervention Type: DRUG; Name: placebos; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: hydrocortisone and fludrocortisone and placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: recombinant human activated protein C and placebos; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: recombinant human activated protein C and hydrocortisone and fludrocortisone; Assigned to Arm(s): 4
D: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Device: Control group | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Drug: blood pressure maintenance based on cerebral blood flow autoregulation measurement | Intervention Type: DRUG; Name: blood pressure maintenance based on cerebral blood flow autoregulation measurement; Assigned to Arm(s): Intervention | Intervention Type: DEVICE; Name: Control group; Assigned to Arm(s): Control

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III of Recombinant Human Activated Protein C and Low Dose of Hydrocortisone and Fludrocortisone in Adult Septic Shock
Brief Summary: This study aims at comparing the efficacy and safety of recombinant human activated protein C to that of low dose of corticosteroids and at investigating the interaction between these drugs in the management of septic shock


Options:
A: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebos | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: hydrocortisone and fludrocortisone and placebo | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human activated protein C and placebos | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human activated protein C and hydrocortisone and fludrocortisone | Intervention Type: DRUG; Name: placebos; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: hydrocortisone and fludrocortisone and placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: recombinant human activated protein C and placebos; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: recombinant human activated protein C and hydrocortisone and fludrocortisone; Assigned to Arm(s): 4
B: Intervention Type: DRUG; Name: intensive insulin therapy to maintain normoglycemia; Assigned to Arm(s): N/A
C: Arm Label: Hydrocortisone; Type: EXPERIMENTAL; Interventions: Drug: Hydrocortisone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Hydrocortisone; Assigned to Arm(s): Hydrocortisone
D: Intervention Type: DRUG; Name: Mythylprednisolone; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III of Recombinant Human Activated Protein C and Low Dose of Hydrocortisone and Fludrocortisone in Adult Septic Shock
Brief Summary: This study aims at comparing the efficacy and safety of recombinant human activated protein C to that of low dose of corticosteroids and at investigating the interaction between these drugs in the management of septic shock


Options:
A: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebos | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: hydrocortisone and fludrocortisone and placebo | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human activated protein C and placebos | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human activated protein C and hydrocortisone and fludrocortisone | Intervention Type: DRUG; Name: placebos; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: hydrocortisone and fludrocortisone and placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: recombinant human activated protein C and placebos; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: recombinant human activated protein C and hydrocortisone and fludrocortisone; Assigned to Arm(s): 4
B: Arm Label: methylprednisolone; Type: EXPERIMENTAL; Interventions: Drug: methylprednisolone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: methylprednisolone; Assigned to Arm(s): methylprednisolone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Prednisone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prednisone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Prednisone | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Placebo, Prednisone
D: Intervention Type: DRUG; Name: hydrocortisone 200 mg/day; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III of Recombinant Human Activated Protein C and Low Dose of Hydrocortisone and Fludrocortisone in Adult Septic Shock
Brief Summary: This study aims at comparing the efficacy and safety of recombinant human activated protein C to that of low dose of corticosteroids and at investigating the interaction between these drugs in the management of septic shock


Options:
A: Intervention Type: DRUG; Name: Drotrecogin Alfa (Activated); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Unfractionated heparin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Low molecular weight heparin; Assigned to Arm(s): N/A
B: Arm Label: Standard therapy; Type: EXPERIMENTAL; Interventions: Drug: Drotrecogin alfa (activated) | Arm Label: Alternative therapy:moderate protein C deficiency; Type: EXPERIMENTAL; Interventions: Drug: Drotrecogin alfa (activated) | Arm Label: Alternative therapy:severe protein C deficiency; Type: EXPERIMENTAL; Interventions: Drug: Drotrecogin alfa (activated) | Intervention Type: DRUG; Name: Drotrecogin alfa (activated); Assigned to Arm(s): Alternative therapy:moderate protein C deficiency, Alternative therapy:severe protein C deficiency, Standard therapy
C: Arm Label: HES 130/0.4; Type: EXPERIMENTAL; Interventions: Drug: 6% Hydroxyethyl starch 130/0.4 | Arm Label: Ringer acetate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ringers acetate | Intervention Type: DRUG; Name: 6% Hydroxyethyl starch 130/0.4; Assigned to Arm(s): HES 130/0.4 | Intervention Type: DRUG; Name: Ringers acetate; Assigned to Arm(s): Ringer acetate
D: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebos | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: hydrocortisone and fludrocortisone and placebo | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human activated protein C and placebos | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human activated protein C and hydrocortisone and fludrocortisone | Intervention Type: DRUG; Name: placebos; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: hydrocortisone and fludrocortisone and placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: recombinant human activated protein C and placebos; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: recombinant human activated protein C and hydrocortisone and fludrocortisone; Assigned to Arm(s): 4

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sex-Differential Health Interventions In Low-Birth-Weight Infants
Brief Summary: Our group has consistently found that the major interventions to reduce morbidity and mortality in low-income countries have sex-differential effects. These interventions include BCG vaccine, oral polio vaccination (OPV), and vitamin A supplementation (VAS).

Low-birth-weight (LBW) children constitute the largest high-risk group in low-income countries. According to current policy, they receive OPV at birth. Current evidence suggests that a policy of providing BCG with OPV for girls and VAS instead of OPV for boys at birth may improve survival in LBW neonates. This will be tested in a large randomized trial.

We experienced an unexpected cluster of deaths among boys in the VAS arm, which could be due to chance, but we decided to stop randomizing boys to OPV or VAS. Very recent evidence has suggested that low-birth-weight boys may benefit from BCG at birth as well. Hence, we have obtained ethical permission to continue the trial with randomization of boys to OPV or OPV plus BCG.


Options:
A: Intervention Type: DRUG; Name: Vitamin A; Assigned to Arm(s): N/A
B: Arm Label: Vitamin A; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin A (retinyl palmitate). | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Vitamin A (retinyl palmitate). | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin A (retinyl palmitate).; Assigned to Arm(s): Placebo, Vitamin A
C: Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin A; Assigned to Arm(s): N/A
D: Arm Label: Boys 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: OPV | Arm Label: Boys 2; Type: EXPERIMENTAL; Interventions: Biological: OPV plus BCG | Arm Label: Girls 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: OPV | Arm Label: Girls 2; Type: EXPERIMENTAL; Interventions: Biological: OPV plus BCG | Intervention Type: BIOLOGICAL; Name: OPV; Assigned to Arm(s): Boys 1 | Intervention Type: BIOLOGICAL; Name: OPV plus BCG; Assigned to Arm(s): Boys 2 | Intervention Type: BIOLOGICAL; Name: OPV; Assigned to Arm(s): Girls 1 | Intervention Type: BIOLOGICAL; Name: OPV plus BCG; Assigned to Arm(s): Girls 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Denufosol Tetrasodium Inhalation Solution in Patients With Cystic Fibrosis Lung Disease and FEV1 Greater Than or Equal to 75% Predicted But Less Than or Equal to 110% Predicted
Brief Summary: The purpose of this trial is to evaluate the safety and effectiveness of one dose strength of Denufosol compared to placebo in patients with CF and a predicted FEV1 of greater than or equal to 75% but less than or equal to 110% predicted.


Options:
A: Arm Label: Comprehensive Adherence Program (CAP); Type: EXPERIMENTAL; Interventions: Behavioral: Comprehensive Adherence Program (CAP) | Arm Label: Standard Care (SC); Type: EXPERIMENTAL; Interventions: Behavioral: Comprehensive Adherence Program (CAP) | Intervention Type: BEHAVIORAL; Name: Comprehensive Adherence Program (CAP); Assigned to Arm(s): Comprehensive Adherence Program (CAP), Standard Care (SC)
B: Intervention Type: DRUG; Name: hypertonic saline; Assigned to Arm(s): N/A
C: Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Denufosol Tetrasodium (INS37217) Inhalation Solution | Intervention Type: DRUG; Name: Denufosol Tetrasodium (INS37217) Inhalation Solution; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Placebo (pooled two times a day [BID]/three times a day [TID]); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo two times a day (BID)/three times a day (TID) | Arm Label: AZLI (pooled two times a day [BID]/three times a day [TID]); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg two times a day (BID)/three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg two times a day (BID)/three times a day (TID); Assigned to Arm(s): AZLI (pooled two times a day [BID]/three times a day [TID]) | Intervention Type: DRUG; Name: Placebo two times a day (BID)/three times a day (TID); Assigned to Arm(s): Placebo (pooled two times a day [BID]/three times a day [TID])

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Ketamine Improves Post-Thoracotomy Analgesia
Brief Summary: Thoracotomy for lung tumor or for minimally invasive direct coronary artery bypass (MIDCAB) surgery, may be associated with debilitating pain. Ketamine was shown to enhance opioid antinociception and prevent opioid resistance. We hypothesize that ketamine given with morphine would lower morphine consumption and narcotic related side effects after thoracotomy and provide superior analgesia to morphine given alone.


Options:
A: Arm Label: morphine only; Type: ACTIVE_COMPARATOR; Interventions: Drug: morphine | Arm Label: morphine ketamine; Type: EXPERIMENTAL; Interventions: Drug: morphine ketamine | Intervention Type: DRUG; Name: morphine; Assigned to Arm(s): morphine only | Intervention Type: DRUG; Name: morphine ketamine; Assigned to Arm(s): morphine ketamine
B: Arm Label: Injection with Saline; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Infiltration with Saline | Arm Label: Injection with Bupivacaine; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Infiltration with Bupivacaine | Intervention Type: PROCEDURE; Name: Infiltration with Saline; Assigned to Arm(s): Injection with Saline | Intervention Type: PROCEDURE; Name: Infiltration with Bupivacaine; Assigned to Arm(s): Injection with Bupivacaine
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: perioperative epidural catheter | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: perioperative epidural catheter | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Procedure: perioperative epidural catheter | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Procedure: perioperative epidural catheter | Arm Label: 5; Type: PLACEBO_COMPARATOR; Interventions: Procedure: perioperative epidural catheter | Intervention Type: PROCEDURE; Name: perioperative epidural catheter; Assigned to Arm(s): 1, 2, 3, 4, 5
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: ropivacaine, ketorelac and epinephrine | Arm Label: P; Type: PLACEBO_COMPARATOR; Interventions: Drug: saline | Intervention Type: DRUG; Name: ropivacaine, ketorelac and epinephrine; Assigned to Arm(s): A | Intervention Type: DRUG; Name: saline; Assigned to Arm(s): P

Answer: A